Skip to main content
NewslettersWatchlist

Ambrx Biopharma Inc ADR(AMAM-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low27.98
Day High28.00
Open:27.99
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Motley Fool
Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson
GlobeNewswire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
MarketBeat
Johnson & Johnson: Biotech a shot in the arm for future growth?
The Globe and Mail
Market movers: Stocks seeing action on Monday - and why
Barchart
Markets Today: Stocks Edge Higher on Hopes Israeli-Hamas Conflict Can Be Contained
Motley Fool
Why Shares of Ambrx Biopharma Soared This Week
Motley Fool
Why Shares of Ambrx Biopharma Jumped This Week
Business Wire
Ambrx Raises $78 Million and Completes its ATM Program
Motley Fool
Why Shares of Ambrx Biopharma Fell Tuesday
MarketBeat
Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Business Wire
Ambrx to Commence Trading on Nasdaq
Business Wire
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results
Business Wire
ARX517, Ambrx’s Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer
Business Wire
Ambrx Biopharma to Host Analyst and Investor Day to Discuss ARX788 in Breast Cancer and ARX517 in Prostate Cancer
Business Wire
Ambrx Biopharma Strengthens Clinical Leadership with Appointment of Sandra Aung, Ph.D. as Head of Clinical Development
Business Wire
Ambrx Biopharma Inc. Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
Business Wire
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Business Wire
Ambrx Announces NovoCodex’s Dosing of First Patient with ARX305, Ambrx’s Investigational Antibody Drug Conjugate Targeting CD70
Business Wire
Ambrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive Officer
Business Wire
Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update
Business Wire
Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian
Business Wire
Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors
Business Wire
Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference
Business Wire
Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors
Business Wire
Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences
Business Wire
Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer
Business Wire
Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences
Business Wire
Ambrx Biopharma Inc. Announces Filing of Annual Report on Form 20-F
Motley Fool
Ambrx Biopharma Inc. (AMAM) Q4 2021 Earnings Call Transcript
Business Wire
Ambrx Biopharma Inc. Reports Full Year 2021 Financial Results; Provides Corporate Update
Business Wire
Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of ARX788 in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer
Business Wire
Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022

Profile

Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.